SAN DIEGO, Oct. 31, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that it will report its third quarter 2018 financial and operating results after the close of U.S. financial markets on Wednesday, November 7, 2018. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
|Conference call and webcast:|
|Date:||November 7, 2018|
|Time:||4:30 pm Eastern Time (1:30 pm Pacific Time)|
|Dial-in:||(855) 779-9066 (Domestic) or (631) 485-4859 (International)|
|Via web:||www.traconpharma.com; “Events and Presentations” section within the “Investors” section|
A replay of the webcast will be available for 60 days on the website.
TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.